| Oct 30 |
ITCI Q3 Loss Wider Than Expected, Revenues Top on Higher Caplyta Sales
|
| Oct 30 |
Intra-Cellular Therapies (ITCI) Reports Q3 Loss, Tops Revenue Estimates
|
| Oct 30 |
Intra-Cellular: Q3 Earnings Snapshot
|
| Oct 30 |
Intra-Cellular Therapies GAAP EPS of -$0.25 misses by $0.04, revenue of $175.4M beats by $3.05M
|
| Oct 30 |
Intra-Cellular Therapies Reports Third Quarter 2024 Financial Results, Provides Corporate Update and Raises 2024 Caplyta Sales Guidance
|
| Oct 29 |
Intra-Cellular Therapies Q3 2024 Earnings Preview
|
| Oct 23 |
Intra-Cellular Therapies (ITCI) Expected to Beat Earnings Estimates: Should You Buy?
|
| Oct 17 |
Intra-Cellular Therapies to Host Third Quarter 2024 Financial Results Conference Call and Webcast
|
| Oct 13 |
Intra-Cellular Therapies, Inc. (ITCI): Among the Most Promising Mid-Cap Stocks According to Hedge Funds
|
| Oct 11 |
Intra-Cellular's Caplyta Sales Boost Revenues, Dependence a Woe
|
